Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

AI Voice Calls Versus Text and Email Reminders for Questionnaire Response After Shoulder Arthroplasty (VOICE-REACH)

Proactive Conversational Artificial Intelligence Calls Versus Digital Reminders to Collect Patient-Reported Outcomes After Shoulder Arthroplasty: A Randomized Study Within a Multicenter Cohort

After shoulder replacement surgery, surgeons send questionnaires to their patients to learn how they are doing (pain, shoulder function, satisfaction). Many patients do not answer. This study tests the best way to obtain these answers.

The study is nested in a multicenter study of pain after shoulder arthroplasty conducted in four French centers (host study RetroPAinRSACAll, supported by Ramsay Santé). The clinical results of the host study are not the subject of this registration: this study evaluates only the method used to collect the information.

All patients first receive an email invitation (when an email address is available) and, the next day, a text message (SMS) with a personal link to the questionnaire and a phone number to answer at any time by talking with an automated voice assistant. Patients who have not answered two days after the first contact are randomly assigned to one of two follow-up strategies: (1) further digital reminders (SMS on day 3 and day 5, email on day 7), or (2) up to three phone calls from a conversational artificial intelligence (AI) voice agent on days 3, 5 and 7, which asks the same questions orally. In both groups, patients can answer at any time online or by calling the voice assistant, and contacts stop as soon as the questionnaire is completed or the patient refuses.

The main outcome is the proportion of patients who complete the questionnaire within 14 days of the first contact.

Panoramica dello studio

Descrizione dettagliata

Design. VOICE-REACH is a pragmatic, multicenter, individually randomized, two-arm, open-label superiority study within a trial (SWAT). It is embedded in the host study RetroPAinRSACAll (persistent pain after shoulder arthroplasty, four French shoulder surgery centers, favorable opinion of the Ramsay Santé scientific committee, reference COS-RGDS-2026-07-008). All patients of the host cohort are contacted through the DeepCall platform on behalf of their surgeon to complete the host study questionnaire (operation details, warning signs, pain screening and characterization, rehabilitation and function including the Subjective Shoulder Value, opinion on the operation and on the contact). The comparison concerns the follow-up strategy only: the questionnaire is the same in both arms and the same on the web and by voice.

Common phase (all participants). Day 0: email invitation with a personal questionnaire link, sent when an email address is available. Day 1: SMS with the same link, the phone number of the AI voice agent (available 24 hours a day for inbound calls) and an opt-out option (reply NO). Patients are contacted in successive waves of up to 450 patients, one day apart, to respect operator sending limits; all study days are counted from each participant's own day 0.

Randomization. On day 2, participants who have not completed the questionnaire and have not refused are randomized 1:1 by the platform, using a computer-generated permuted block sequence (blocks of 4) stratified by center. Participants who completed the questionnaire before day 2 are not randomized and are described separately.

Arm A, digital reminders: SMS reminders on day 3 and day 5 and an email reminder on day 7 (when an email address is available).

Arm B, proactive AI calls: outbound calls from the AI voice agent on day 3, day 5 and day 7 (up to three attempts). The agent calls on behalf of the surgeon's team and asks the questionnaire orally; answers are extracted into the same structured fields as the web form.

In both arms, the web link and the inbound voice line remain available throughout, and all scheduled contacts stop as soon as the questionnaire is completed, the patient refuses, or the patient is identified as deceased. Warning signs reported by patients are flagged to the surgical team for review; the AI agent does not give medical advice.

Analysis. The primary analysis is intention to treat among all randomized participants: proportion with a completed questionnaire by day 14, risk difference (Arm B minus Arm A) with 95% confidence interval, adjusted for center and email availability. Participants without a completed questionnaire by day 14 are counted as non-completers; no answer is imputed. Secondary analyses describe the yield of the common phase, time to completion, completion channel, partial responses, refusals, number of contacts and cost per completed questionnaire, acceptability of the contact mode among responders, representativeness of responders, and the accuracy of voice-captured answers.

Registration timing. The common pre-randomization outreach started on 9 November 2026. This record was created on 10 November 2026, before the first randomization (day 2 of the first wave, 11 November 2026).

Tipo di studio

Interventistico

Iscrizione (Stimato)

846

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

      • Caen, Francia, 14000
        • Reclutamento
        • Hôpital Privé Saint-Martin
        • Investigatore principale:
          • Franck Dordain, MD
      • Lyon, Francia, 69008
        • Reclutamento
        • Centre Orthopédique Santy, Hôpital Privé Jean Mermoz
        • Investigatore principale:
          • Arnaud Godenèche, MD
      • Paris, Francia, 75019
        • Reclutamento
        • Clinique des Maussins-Nollet
        • Investigatore principale:
          • Geoffroy Nourissat, MD, PhD
      • Strasbourg, Francia, 67000
        • Reclutamento
        • Clinique de l'Orangerie
        • Investigatore principale:
          • Maxime Antoni, MD

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Age 18 years or older
  • Shoulder arthroplasty (reverse, anatomic, humeral head replacement or revision arthroplasty) performed at one of the four participating centers and listed in the host study cohort
  • At least one telephone number available (an email address is not required)

Additional criteria for randomization (day 2):

* Questionnaire not completed and no refusal at the day-2 cutoff

Exclusion Criteria:

  • Death identified before the first contact (cross-check with the French national death registry, INSEE)
  • Duplicate record
  • Refusal of contact
  • Questionnaire already completed before day 2 (excluded from randomization only, described separately)

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Ricerca sui servizi sanitari
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Digital Reminders

Common phase: email invitation on day 0 (if an email address is available) and SMS invitation on day 1 with the questionnaire link and the AI voice agent phone number. After randomization on day 2: SMS reminder on day 3, SMS reminder on day 5 and email reminder on day 7 (if an email address is available). Participants can answer at any time by web link or by calling the AI voice agent. Contacts stop at completion or refusal.

Standardized reminder messages sent by the DeepCall platform on behalf of the surgeon: SMS on day 3 and day 5 and email on day 7 (if an email address is available), each with the personal questionnaire link, the AI voice agent phone number and an opt-out option.

Sperimentale: Proactive AI Voice Calls

Same common phase (email on day 0 if available, SMS on day 1). After randomization on day 2: up to three outbound calls from the conversational AI voice agent on day 3, day 5 and day 7, during which the same questionnaire is asked orally. Participants can also answer at any time by web link or by calling the AI voice agent. Contacts stop at completion or refusal.

Outbound telephone calls placed by a conversational AI voice agent (DeepCall platform) on day 3, day 5 and day 7, up to three attempts. The agent calls on behalf of the surgeon's team, conducts the same questionnaire orally and records the answers in the same structured fields as the web form.

Altri nomi:
  • DeepCall

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Questionnaire Completion by Day 14 Among Randomized Participants
Lasso di tempo: From day 0 (first contact) to day 14

Proportion of randomized participants with a completed questionnaire within 14 days of their first contact (day 0), whatever the channel used (web link, inbound call or outbound AI call). A questionnaire is complete when it was submitted on the web or when all required items were answered during a voice interview. Participants without a completed questionnaire at the day-14 cutoff are counted as non-completers. Compared between arms (proactive AI voice calls minus digital reminders).

From day 0 (first contact) to day 14

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Questionnaire Completion by Day 7 Among Randomized Participants
Lasso di tempo: From day 0 to day 7

Proportion of randomized participants with a completed questionnaire by day 7, whatever the channel used.

From day 0 to day 7
Time to Questionnaire Completion
Lasso di tempo: From day 2 to day 14

Time in hours from randomization (day 2) to questionnaire completion among randomized participants; participants without a completed questionnaire are censored at day 14.

From day 2 to day 14
Questionnaire Completion Before Randomization
Lasso di tempo: From day 0 to day 2

Proportion of all enrolled participants who completed the questionnaire after the common email (day 0) and SMS (day 1) invitations, before the day-2 randomization.

From day 0 to day 2
Questionnaire Completion by Day 14 in All Enrolled Participants
Lasso di tempo: From day 0 to day 14

Proportion of all enrolled participants, randomized or not, with a completed questionnaire by day 14.

From day 0 to day 14
Partial Questionnaire Response
Lasso di tempo: From day 0 to day 14

Proportion of randomized participants who answered at least one question without completing the questionnaire by day 14.

From day 0 to day 14
Completion Channel
Lasso di tempo: From day 0 to day 14

Distribution of completed questionnaires by channel (web link, inbound call to the voice agent, outbound AI call), by arm.

From day 0 to day 14
Refusal of Contact
Lasso di tempo: From day 2 to day 14

Proportion of randomized participants who explicitly refused further contact (SMS reply, email refusal link or refusal during a call).

From day 2 to day 14
Number of Contacts per Completed Questionnaire
Lasso di tempo: From day 0 to day 14

Number of emails, SMS and outbound calls sent or attempted, divided by the number of completed questionnaires, by arm.

From day 0 to day 14
Direct Cost per Completed Questionnaire
Lasso di tempo: From day 0 to day 14

Direct costs of messaging, telephony and AI processing (euros) divided by the number of completed questionnaires, by arm, and incremental cost per additional completed questionnaire.

From day 0 to day 14
Satisfaction With the Mode of Contact
Lasso di tempo: From day 0 to day 14

Among participants who completed the questionnaire: satisfaction with the way they were contacted, rated on a 5-level scale from very satisfied to very dissatisfied.

From day 0 to day 14
Perceived Number of Contacts
Lasso di tempo: From day 0 to day 14

Among participants who completed the questionnaire: perceived number of contacts (too many, appropriate, too few).

From day 0 to day 14
Preferred Contact Mode for Future Follow-up
Lasso di tempo: From day 0 to day 14

Among participants who completed the questionnaire: preferred mode of contact for future follow-up questionnaires (categorical).

From day 0 to day 14
Characteristics of Responders Versus Non-Responders
Lasso di tempo: Day 14

Age, center, type of arthroplasty and time since surgery (when available in the host cohort) compared between participants who completed the questionnaire and those who did not, by arm (standardized differences).

Day 14
Agreement Between Voice-Captured Answers and Human Review
Lasso di tempo: From day 0 to day 14

In a random sample of completed voice interviews, agreement between the answers extracted by the AI agent and those coded by a reviewer listening to the recording, blinded to the extracted values (percentage agreement, kappa or intraclass correlation coefficient).

From day 0 to day 14

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Delivery of Email and SMS Invitations
Lasso di tempo: From day 0 to day 7

Proportion of emails and SMS delivered, bounced or filtered by the operator, as reported by the sending providers.

From day 0 to day 7
Outbound Call Outcomes
Lasso di tempo: From day 3 to day 7

Distribution of outbound AI call outcomes (answered, voicemail, no answer, filtered, failed) and call duration in the proactive AI voice calls arm.

From day 3 to day 7

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Jules Descamps, MD, MSc, Hopital Lariboisière
  • Cattedra di studio: Geoffroy Nourissat, MD, PhD, Clinique des Maussins-Nollet, Ramsay Santé

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

9 novembre 2026

Completamento primario (Stimato)

24 novembre 2026

Completamento dello studio (Stimato)

24 novembre 2026

Date di iscrizione allo studio

Primo inviato

10 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

10 novembre 2026

Primo Inserito (Effettivo)

17 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

17 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

10 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

Identifiable data, call recordings and transcripts will not be shared. Aggregated results will be published.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi